TBCRC 050 UAB 17112-A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer

Grant

Date/time Interval

  • August 8, 2019 - August 7, 2024
  • Total Award Amount

  • 159300.00
  • Direct Costs

  • 122538.00
  • Sponsor Award Id

  • Contributor

  • Eddy Yang M.D., Ph.D.   Investigator  
  • Erica Stringer-Reasor M.D.   Principal Investigator  
  • Gabrielle Rocque M.D.   Investigator